We believe the Latin American cannabis operator is in the early innings of a major growth cycle and is well positioned to capitalize on a burgeoning market.
One of the reasons we are excited about Khiron is related to the structure of the business and the markets it is focused on.
Last week, Khiron reported a major milestone and formed a strategic partnership with the Colombia Cancer League, which has 60 years of experience in the country as a leading institution in the provision of oncology services.
We are excited about the growth prospects that are associated with the campaign and the 21 medical clinics located throughout the country which are partnering with Khiron and the Colombia Cancer League.
The campaign aims to improve safe access to consultations for medical cannabis and will be conducted in 11 cities across the country.
So far this year, Khiron has shown excellent execution and we are bullish on how the story has advanced.
During this time, Khiron has filled over 19,000 prescriptions.
We are favorable on the recent uptick in business to Colombia offering insurance to medical cannabis patients and this is trend that we expect to serve as a major revenue generator for it.
Going forward, we expect Khiron to be a major beneficiary of an increase in the amount of external health care providers that have finished the company’s medical cannabis education program.
2021 is already proving to be a banner year for Khiron and we expect the Latin American cannabis company to report major milestones in the back half of the year.
In Florida, Trulieve has the most medical cannabis dispensaries and has been capitalizing on the cannabis opportunity in the state.
Going forward, we expect Khiron to sell a record amount of cannabis and expect the change in how insurance covers the cost of medical cannabis for approved patients to serve as a major catalyst for growth.
As the management team continues to execute in these markets, we expect to see more interest in the opportunity and this an operator that our readers should be aware of.
Pursuant to an agreement between StoneBridge Partners LLC and Khiron Life Sciences Inc.
This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws, including statements related to the Company’s ability to support its continued growth and fund the business’ sales and financial goals for at least the remainder of fiscal 2021 with proceeds remaining from its recent offering.
All information that we provide is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.